FDA Clearance Tracker · P200010-S029
Guardant360 CDx
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 18, 2026
Approved
Time to decision
190 days
Received Mar 12, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P200010-S029
- Device name
- Guardant360 CDx
- Applicant
- Guardant Health, Inc.
- Applicant location
- Redwood City, CA
- Received
- Mar 12, 2026
- Decided
- Sep 18, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P200010
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for expanding the intended use and indications for use of Guardant360 CDx to include a companion diagnostic indication for the detection of ESR1 mutations in Breast Cancer (BC) patients who may benefit from treatment with INLURIYO (imlunestrant) in combination with VERZENIO (abemaciclib).
Source documents
Other decisions for Guardant Health, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250027 · Decided May 19, 2026 · 292 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.